OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine

OncBioMune Readies for Enrollment in Phase 2 Trial of ProscaVax Vaccine
OncBioMune Pharmaceuticals soon will initiate a Phase 2 trial evaluating the effectiveness and safety of its lead immunotherapy, ProscaVax, for men with early-stage prostate cancer. In a recent update, the company announced that the initial installments needed for the study have been made, and final preparations for patient enrollment are being completed. The Phase 2 study (NCT03579654) will

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *